Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis

Acta Neurologica Scandinavica

Volumn 93, Issue 2-3, 1996, Pages 99-103

  Acarin N ^a   Rio J ^a   Fernandez A L ^a   Tintore M ^a   Duran I ^a   Galan I ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiganglioside antibody; ELISA; Progressive MS; Relapsing remitting MS

Indexed keywords

GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS;

EID: 0029874261     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1996.tb00182.x     Document Type: Article

References (29)

1. COMPSTON A. Immunological aspects of multiple sclerosis. In: MATTHEWS WB, COMPSTON A, ALLEN IV, MARTYN CN, ed. McAlpine's multiple sclerosis. 2nd edn. Edinburgh: Churchill Livingstone, 1991: 321-339.
2. MCFARLIN DE, MCFARLAND H. Multiple sclerosis. N Engl J Med 1982: 307: 1183-1188.
3. PESTRONK A, CORNBLATH DR, ILYAS AA et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988: 24: 73-78.
4. ILYAS AA, MITHEN FA, CHEN ZW, COOK SD. Search for antibodies to neutral glycolipids in sera of patients with Guillain-Barré syndrome. J Neurol Sci 1991: 102: 67-75.
5. STEVENS A, WELLER M, WIETHÖLTER H. CSF and serum ganglioside antibody patterns in MS. Acta Neurol Scand 1992: 86: 485-489.
6. ARNON R, CRISP E, KELLEY R, ELLISON GW, MYERS LW, TOURTELLOTTE WW. Anti-ganglioside antibodies in multiple sclerosis. J Neurol sci 1980: 40: 179-186.
7. ENDO T, SCOTT DD, STEWART SS, KUNDU SK, MARCUS DM. Antibodies to glycosphingolipids in patients with multiple sclerosis and SLE. J Immunol 1984: 132: 1793-1797.
8. FEIX JB, KHATRI B, MCQUILLEN MP, KOETHE SM. Immune reactivity against membranes containing ganglioside GM1 in chronic-progressive multiple sclerosis: observation by spin-membrane immunoassay. Immunol Commun 1984: 13: 465-474.
9. MATHIESEN T, VON HOLST H, FREDRIKSON S et al. Total, anti-viral, and anti-myelin IgG subclass reactivity in inflammatory diseases of the central nervous system. J Neurol 1989: 236: 238-242.
10. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: guidelines for research proposals. Ann Neurol 1983: 13: 227-231.
11. TAN EM, COHEN AS, FRIES JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982: 25: 1271-1280.
12. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983: 33: 1444-1452.
13. MARTINEZ X, TINTORÉ M, MONTALBÁN J, ORDI J, VILARDELL M, CODINA A. Antibodies against gangliosides in patients with SLE and neurological manifestations. Lupus 1992: 1: 299-302.
14. FIERZ W. MS as autoimmune disease: myelin antigens. 25th Forum in Immunology: immunological aspects of multiple sclerosis. Res Immunol 1989: 140: 181-186.
15. RAINE CS, TRAUGOTT U. The pathogenesis and therapy of multiple sclerosis is based upon the requirement of a combination of myelin antigens for autoimmune demyelination. J Neuroimmunol 1982: 2: 83-91.
16. SUN JB, LINK H, XIAO BG et al. T and B cell responses to myelin oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 1991: 146: 1490-1495.
17. SUN JB, OLSSON T, WANG WZ et al. Autoreactive T and B cells responding to proteolipid protein in multiple sclerosis. Eur J Immunol 1991: 21: 1461-1468.
18. OLSSON T, BAIG S, HÖJERBERG B, LINK H. Antimielin basic protein and myelin antibody producing cells in multiple sclerosis. Ann Neurol 1990: 27: 132-136.
19. SAIDA K, SAIDA T, BROWN MJ, SILBERBERG DH. In vivo demyelination induced by intraneural injection of antigalactocerebroside serum. A morphological study. Am J Pathol 1979: 95: 99-116.
20. SERGOTT RC, BROWN MJ, SILBERBERG DH, ROBERT P. Antigalactocerebroside serum demyelinates optic nerve in vivo. J Neurol Sci 1984: 64: 297-303.
21. KASAI N, PACHNER AR, YU RK. Anti-glycolipid antibodies and their immune complexes in multiple sclerosis. J Neurol Sci 1986: 75: 33-42.
22. MATTHEWS WB. Clinical aspects. In: MATTHEWS WB, COMPSTON A, ALLEN IV, MARTYN CN, ed. McAlpine's multiple sclerosis. 2nd ed. Edinburgh: Churchill Livingstone, 1991: 49-72.
23. TROTTER JL, CLIFFORD DB, MCINNIS JE et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 1989: 25: 172-178.
24. MCDONALD WI, HALLIDAY AM. The diagnosis and classification of multiple sclerosis. Br Med Bull 1977: 33: 4-8.
25. HENNEBERG AE, ELSNER U, KORNHUBER HH. Absence of brain antibodies in the sera of relapsing-remitting multiple sclerosis patients is not due to the formation of immune complexes. Acta Neurol scand 1993: 87: 455-456.
26. THOMPSON EJ, KAUFMANN P, RUDGE P. Sequential changes in oligoclonal patterns during the course of multiple sclerosis. J Neurol Neurosurg Psychiatry 1983: 46: 115-118.
27. MILLER DH, BARKHOF F, BERRY I, KAPPOS L, SCOTTI G, THOMPSON AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991: 54: 683-688.
28. BARNES D, MUNRO PMG, YOUL BD, PRINEAS JW, MCDONALD WI. The longstanding MS lesion. A quantitative MRI and electron microscopy study. Brain 1991: 114: 1271-1280.
29. MCDONALD WI. Pathophysiology of multiple sclerosis. In: MCDONALD WI, SILBERBERG DH, eds. Multiple sclerosis. London: Butterworths, 1986: 128-129.